M.K. AlisdairiManaging Director, Advisory
Mr. Alisdairi is a Managing Director in Perella Weinberg Partners’ Advisory business. He focuses on advising clients in the Healthcare sector.
Mr. Alisdairi has more than 15 years of investment banking experience assisting companies on a wide range of strategic matters. During his tenure at Perella Weinberg Partners, he has advised Becton Dickinson in its acquisition of C. R. Bard for $24 billion; Sprout Pharmaceuticals in its sale to Valeant Pharmaceuticals for $1 billion plus milestones; Lumara Health in its sale of assets to Perrigo; Lumara Health in its sale to AMAG Pharmaceuticals for $1 billion; and AMAG Pharmaceuticals in connection with a $300 million convertible offering, among others. Mr. Alisdairi has also advised on a number of complex situations outside of the Healthcare sector including Apollo Global Management and Athene Holding in the acquisition of Investors Insurance Corporation; Warburg Pincus in its acquisition of an anchor investment in Primerica from Citigroup concurrently with the IPO of Primerica; and the office of the Chairwoman Sheila Bair of the FDIC in matters relating to the global financial crisis of 2008 and the recapitalization of the US banking system, among others.
Prior to joining Perella Weinberg Partners during its founding in 2006, Mr. Alisdairi was at UBS Investment Bank where he was most recently a member of the Global Mergers & Acquisitions Group advising on transactions in a number of sectors including Healthcare, Consumer Products and Real Estate.
Mr. Alisdairi earned a Master of Science from Columbia University and a Bachelor of Science from Bucknell University.